Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.32 |
| ▸ | FEN1 | P39748 | 3/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886824 | 0.85 | S1PR4 (0.36) | DGAT1 | |
| SCHEMBL2885996 | 0.83 | BMPR1B (0.36) | DGAT1ALOX5APFEN1 | |
| SCHEMBL20589968 | 0.79 | ROCK2 (0.36) | DGAT1ALOX5APFEN1FLT3 | |
| SCHEMBL2888150 | 0.77 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL25238455 | 0.74 | BRAF (0.39) | — | |
| SCHEMBL2887530 | 0.74 | POLB (0.36) | DGAT1 | |
| SCHEMBL4246766 | 0.74 | AXL (0.38) | DGAT1ALOX5APFEN1 | |
| SCHEMBL20422628 | 0.73 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL29854683 | 0.73 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL29663834 | 0.73 | DGAT1 (0.43) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| US-7723347-B2 | Substituted phenylamino-pyrimidines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1742945-B1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER SCHERING PHARMA AG (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1742945-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | Bayer HealthCare AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005108397-A1 | SUBSTITUTED PHENYLAMINO-PYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269268-A1 | Substituted Phenylamino-Pyrimidines | TYMP, DPYD, HPRT1 | DGAT1 4366/4885ALOX5AP 806/4885FEN1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.